Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
New drug duo targets advanced lung cancer in groundbreaking chinese trial
Disease control OngoingThis study is testing a combination of two drugs, encorafenib and binimetinib, for Chinese adults with a specific advanced form of lung cancer (BRAF V600E mutated NSCLC). The main goals are to see how well the drugs shrink tumors and to monitor their safety. The trial is for pati…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug trial targets Hard-to-Treat cancer mutations
Disease control OngoingThis early-stage study is testing a new oral drug called KIN-2787 in adults with advanced solid tumors that have specific BRAF or NRAS gene mutations, including lung cancer and melanoma. The main goals are to find a safe dose, see how the body processes the drug, and get an early…
Phase: PHASE1 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC